Login

Financial Snapshot

Revenue
TTM
$57.14M
Gross Margin
TTM
75.85%
Net Income
TTM
$8.763M
Current Assets
2026 Q1
$79.00M
Current Liabilities
2026 Q1
$24.00M
Current Ratio
2026 Q1
329.17%
Total Assets
2026 Q1
$117.0M
Total Liabilities
2026 Q1
$41.00M
Book Value
2026 Q1
76.00M
Cash
Last 4 Quarters
N/A
P/E
TTM
196.7
Free Cash Flow
TTM
$10.87M

Stock Price

Loading...
Market Cap: $1.7238 Billion

About Brainsway Ltd

Brainsway Ltd. engages in the development and sale of non-invasive neurostimulation treatments using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The firm primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.

Industry: Surgical & Medical Instruments & Apparatus Peers: Alpha Tau Medical Ltd Nano-X Imaging Ltd

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support